Silvia Lazzarelli

523 total citations · 1 hit paper
24 papers, 239 citations indexed

About

Silvia Lazzarelli is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Silvia Lazzarelli has authored 24 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 7 papers in Surgery. Recurrent topics in Silvia Lazzarelli's work include Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Renal cell carcinoma treatment (5 papers). Silvia Lazzarelli is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Renal cell carcinoma treatment (5 papers). Silvia Lazzarelli collaborates with scholars based in Italy, Australia and France. Silvia Lazzarelli's co-authors include Caterina Caminiti, Matteo Puntoni, Giuseppe Maglietta, Barbara Marcomini, Francesca Diodati, Laura Patrizi, Rodolfo Passalacqua, Sebastiano Buti, Maddalena Donini and Matteo Brighenti and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Silvia Lazzarelli

24 papers receiving 237 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis

2022 111 citations Giuseppe Maglietta, Francesca Diodati et al. Journal of Clinical Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Silvia Lazzarelli Italy	9	104	88	57	55	46	24	239
Weitao Zhuang China	10	31 0.3×	72 0.8×	91 1.6×	25 0.5×	12 0.3×	44	224
Daniel Antwi‐Amoabeng United States	9	70 0.7×	89 1.0×	33 0.6×	9 0.2×	93 2.0×	38	280
Giorgia Camera Italy	9	207 2.0×	17 0.2×	10 0.2×	45 0.8×	85 1.8×	12	288
Syeda B. Ahmad United States	6	47 0.5×	43 0.5×	33 0.6×	25 0.5×	134 2.9×	12	259
Morten Tulstrup Denmark	8	116 1.1×	22 0.3×	6 0.1×	73 1.3×	48 1.0×	17	339
Vishal P. Shah United States	9	58 0.6×	29 0.3×	52 0.9×	13 0.2×	88 1.9×	11	264
Artur Zaczyński Poland	10	104 1.0×	39 0.4×	20 0.4×	19 0.3×	95 2.1×	34	256
Shimaa Afify Egypt	10	33 0.3×	29 0.3×	14 0.2×	18 0.3×	75 1.6×	33	314
Nikhil Huprikar United States	8	63 0.6×	9 0.1×	76 1.3×	11 0.2×	44 1.0×	19	182
Marie Thys Belgium	8	69 0.7×	24 0.3×	68 1.2×	15 0.3×	69 1.5×	22	190

Countries citing papers authored by Silvia Lazzarelli

Since Specialization

Citations

This map shows the geographic impact of Silvia Lazzarelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Lazzarelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Lazzarelli more than expected).

Fields of papers citing papers by Silvia Lazzarelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Lazzarelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Lazzarelli. The network helps show where Silvia Lazzarelli may publish in the future.

Co-authorship network of co-authors of Silvia Lazzarelli

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Lazzarelli. A scholar is included among the top collaborators of Silvia Lazzarelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Lazzarelli. Silvia Lazzarelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maglietta, Giuseppe, Francesca Diodati, Matteo Puntoni, et al.. (2022). Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 11(6). 1541–1541. 111 indexed citations breakdown →

Caminiti, Caterina, Giuseppe Maglietta, Francesca Diodati, et al.. (2022). The Effects of Patient-Reported Outcome Screening on the Survival of People with Cancer: A Systematic Review and Meta-Analysis. Cancers. 14(21). 5470–5470. 25 indexed citations

Passalacqua, Rodolfo, Silvia Lazzarelli, Maddalena Donini, et al.. (2017). Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014). BMC Cancer. 17(1). 493–493. 4 indexed citations

Tomasello, Gianluca, Nicola Valeri, Michele Ghidini, et al.. (2017). First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. Oncotarget. 8(67). 111795–111806. 4 indexed citations

Panni, Stefano, Silvia Lazzarelli, Matteo Brighenti, et al.. (2017). High baseline lymphocyte count is a predictive biomarker of prolonged time to progression in patients with advanced solid tumors receiving checkpoint inhibitors.. Journal of Clinical Oncology. 35(15_suppl). e14532–e14532. 3 indexed citations

Cinieri, Saverio, Arlene Chan, Kadri Altundağ, et al.. (2016). Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. 17(2). 91–99.e1. 8 indexed citations

Passalacqua, Rodolfo, Silvia Lazzarelli, Rodolfo Montironi, et al.. (2016). Vinflunine (VFL) in patients (pts) with metastatic transitional cell carcinoma of the urothelial tract (mTCCU): Clinical outcome and prognostic factors in a nationwide, real-life setting (MOVIE trial).. Journal of Clinical Oncology. 34(15_suppl). e16031–e16031. 4 indexed citations

Tomasello, Gianluca, Silvia Lazzarelli, Federica Negri, et al.. (2016). Safety and Efficacy of Dose-dense Chemotherapy with TCF Regimen in Elderly Patients with Locally Advanced or Metastatic Gastric Cancer. Tumori Journal. 103(1). 93–100. 2 indexed citations

Donini, Maddalena, Rodolfo Passalacqua, Rodolfo Montironi, et al.. (2015). Effectiveness and possible molecular factors predictive of clinical outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: a multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Annals of Oncology. 26. vi53–vi53. 1 indexed citations

10.

Passalacqua, Rodolfo, Rodolfo Montironi, Silvia Lazzarelli, et al.. (2015). 2639 Effectiveness and possible Molecular factors predictive of clinical Outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: A multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). European Journal of Cancer. 51. S526–S527. 1 indexed citations

11.

Tomasello, Gianluca, Rodolfo Mattioli, Federica Negri, et al.. (2015). First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5- fluorouracil (DCF) plus panitumumab (P) in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction (GEJ): A phase II multicenter trial.. Journal of Clinical Oncology. 33(3_suppl). 146–146. 1 indexed citations

12.

Donini, Maddalena, Sebastiano Buti, Silvia Lazzarelli, et al.. (2014). Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). Targeted Oncology. 10(2). 277–286. 9 indexed citations

13.

Cinieri, Saverio, Arlene Chan, Kadri Altundağ, et al.. (2014). Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial).. Journal of Clinical Oncology. 32(15_suppl). 1044–1044. 3 indexed citations

14.

Bersanelli, Melissa, Sebastiano Buti, Roberta Camisa, et al.. (2014). Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy. Cancers. 6(4). 2035–2048. 10 indexed citations

15.

Tomasello, Gianluca, Silvia Lazzarelli, Matteo Brighenti, et al.. (2013). Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial. Gastric Cancer. 17(4). 711–717. 10 indexed citations

16.

Passalacqua, Rodolfo, et al.. (2011). 7138 POSTER High Rate of Complete Remission (CR) Using Two Sequential, Dose-dense Regimens of Cisplatin, Gemcitabine, and Paclitaxel (CGP) Followed by HD-MVAC in Patients With Metastatic Bladder Cancer (mBC). European Journal of Cancer. 47. S516–S516. 1 indexed citations

17.

Buti, Sebastiano, Silvia Lazzarelli, Cecilia Simonelli, et al.. (2010). Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study. Journal of Immunotherapy. 33(7). 735–741. 9 indexed citations

18.

Tomasello, Gianluca, Sebastiano Buti, Matteo Brighenti, et al.. (2010). Dose-dense Chemotherapy in Metastatic Gastric Cancer with a Modified Docetaxel-Cisplatin-5-Fluorouracil Regimen. Tumori Journal. 96(1). 48–53. 10 indexed citations

19.

Tomasello, Gianluca, et al.. (2010). Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial. Cancer Chemotherapy and Pharmacology. 67(1). 41–48. 3 indexed citations

20.

Passalacqua, Rodolfo, Sebastiano Buti, Licia Rivoltini, et al.. (2008). Bevacizumab (B) plus low-doses immunotherapy (IT) plus chemotherapy (CT) (BIC) in metastatic renal cell cancer (mRCC): Antitumor effects and variations of T-regulatory cells (Treg) and other T lymphocytes subsets. A study of the Italian Oncology Group for Clinical Research (GOIRC). Journal of Clinical Oncology. 26(15_suppl). 5121–5121. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact